Form 4: Edgewise Therapeutics Director and 10% Owner Acquires 30,000 Stock Options

Peter A. Thompson, a Director and 10% Owner of Edgewise Therapeutics, Inc., acquired 30,000 stock options with an exercise price of $14.68, set to vest by June 2026.

Summary

• Peter A. Thompson, identified as a Director and 10% Owner of Edgewise Therapeutics, Inc. (EWTX), reported an acquisition of derivative securities.
• The transaction occurred on June 16, 2025, involving the grant of 30,000 stock options.
• Each stock option has an exercise price of $14.68.
• The options are set to vest 100% on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.
• These stock options will expire on June 16, 2035.
• Following this transaction, Peter A. Thompson directly beneficially owns 30,000 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The acquisition of stock options by a director and 10% owner can be interpreted as a positive signal of confidence in the company's future prospects, although the filing itself is a routine regulatory disclosure.

Positives

• The acquisition of 30,000 stock options by a Director and 10% Owner, Peter A. Thompson, can be interpreted as a signal of confidence in the company's future performance and long-term value.
• The stock options have a long expiration date of June 16, 2035, providing a significant window for the options to become in-the-money and for the holder to realize potential gains.

Negatives

• No explicit negatives are reported in this Form 4 filing, which primarily details an insider stock option acquisition.

Risks

• This Form 4 filing does not contain information regarding company-specific risks; it is a disclosure of an insider transaction.

Future Outlook

This Form 4 filing does not provide forward-looking statements or guidance regarding the company's future performance or outlook, as it is a regulatory disclosure of an insider transaction.

Management Comments

• This Form 4 filing does not contain direct management comments or notable quotes, as it is a regulatory disclosure of an insider transaction.

Industry Context

This Form 4 filing, detailing an insider stock option acquisition, does not provide broader industry context or trends.

Comparison to Industry Standards

• This Form 4 filing, which reports an insider transaction, does not provide data for comparison to industry standards or specific comparable companies/projects.

Related Party Transactions

• The reported transaction involves Peter A. Thompson, a Director and 10% Owner, acquiring stock options from Edgewise Therapeutics, Inc., which constitutes a related party transaction.

Stakeholder Impact

• Shareholders may view the acquisition of stock options by a director and 10% owner as a positive indicator of management's belief in the company's long-term value, potentially influencing investor sentiment.
• The exercise of these options in the future could lead to a slight dilution of existing shares, depending on the company's outstanding share count at that time.

Next Steps

• The stock options are scheduled to vest on the earlier of June 16, 2026, or the business day prior to the 2026 annual meeting of stockholders.
• Peter A. Thompson may choose to exercise these options at any time after vesting and before their expiration date of June 16, 2035.

Key Dates

Keywords

Edgewise Therapeutics, EWTX, Peter Thompson, Stock Options, Insider Trading, Form 4, SEC Filing, Director, 10% Owner, Equity Compensation